MARKET

MIRM

MIRM

Mirum Pharmaceuticals
NASDAQ
24.49
+0.47
+1.96%
After Hours: 25.37 +0.88 +3.59% 18:35 04/25 EDT
OPEN
23.56
PREV CLOSE
24.02
HIGH
24.62
LOW
23.14
VOLUME
817.34K
TURNOVER
0
52 WEEK HIGH
35.56
52 WEEK LOW
23.14
MARKET CAP
1.15B
P/E (TTM)
-6.1272
1D
5D
1M
3M
1Y
5Y
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 2d ago
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Mirum Pharmaceuticals, Inc. Had a huge miss with a phase 2 study of its drug Limvarli for the treatment of biliary artesia in December 2023. Despite this, the biotech was still able to obtain FDA approval of the drug. The drug is being developed to treat liver disorders. Mirum will release results from two other ongoing phase 2b studies in mid-2024. These studies use another drug being developed in the pipeline, an iBAT inhibitor.
Seeking Alpha · 3d ago
Weekly Report: what happened at MIRM last week (0415-0419)?
Weekly Report · 3d ago
Some Bubbles Are Starting To Pop
The S&P 500 posted its worst weekly performance since March of 2023 this week. The yield on the 10-Year Treasury has risen to 4.62% from 3.9% in late February. Bubbles in the AI sector and high beta parts of the market are deflating. Rising interest rates are also impacting the commercial real estate sector.
Seeking Alpha · 4d ago
Stifel starts Mirum at buy, cites IBATi drug potential
Seeking Alpha · 04/18 14:39
Analyst Ratings For Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for debilitating rare and orphan diseases. The company has an average price target of $52.0. 9 analysts have shared their insights on Mirum pharmaceuticals in the last three months. The 12-month price targets have decreased by 2.42%. The company is expected to reach $72.00 in the next year.
Benzinga · 04/17 13:00
Mirum Pharmaceuticals Initiated at Buy by Stifel
Dow Jones · 04/17 11:24
Mirum Pharmaceuticals Price Target Announced at $48.00/Share by Stifel
Dow Jones · 04/17 11:24
More
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Webull offers Mirum Pharmaceuticals Inc stock information, including NASDAQ: MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.